NGM Biopharmaceuticals, Inc. / Estimates

Fiscal Year	Revenue	Net income	Net margin	Free cash flow	FCF margin
2023	€3.81M -92.0%	-€122.81M -10.5%	-3,223.3% -29 pp	-€112.96M -8.2%	-2,964.7% -27 pp
2022	€47.73M -29.0%	-€137.23M +39.8%	-287.5% -1.4 pp	-€122.99M +99.3%	-257.7% -1.7 pp
2021	€67.18M -10.9%	-€98.19M +21.1%	-146.2% -0.39 pp	-€61.71M -12.3%	-91.9% +0.016 pp
2020	€75.36M -15.6%	-€81.08M +229.8%	-107.6% -0.80 pp	-€70.40M +116.6%	-93.4% -0.57 pp
2019	€89.32M -4.7%	-€24.58M +5,680.5%	-27.5% -0.27 pp	-€32.51M +2,049.7%	-36.4% -0.35 pp
2018	€93.73M +40.9%	-€425.26K -96.5%	-0.5% +0.18 pp	-€1.51M -84.1%	-1.6% +0.13 pp
2017	€66.54M -9.9%	-€12.21M +104.6%	-18.4% -0.10 pp	-€9.48M -142.2%	-14.2% -0.45 pp
2016	€73.83M	-€5.97M	-8.1%	€22.49M	30.5%